Atlas Trials

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Clinical trial NCT02317159 · UNKNOWN

Trial details

NCT number
NCT02317159
Sponsor
Cttq
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Chronic Myeloid Leukemia
Start date
2015-02-01
Primary completion
2017-06-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.